1997a, 1997b), intensive search is still going on for suitable laboratory models in which the various parameters of immunity against HPV-induced tumours could be investigated. We reported previously the isolation of oncogenic Syrian hamster cell lines after transfection of secondary kidney cells with HPV16 E6/E7 genes and activated H-ras oncogene and described specific immune reactions (both humoral and cell-mediated) in animals bearing tumours elicited by these cells . In a subsequent study (Bubeník et al, 1996) , protection against challenge with these cells was induced by inoculation of irradiated homologous tumour cells, and this immunity was significantly enhanced by the simultaneous administration of mouse interleukin-2 (mIL-2); we had previously shown that mIL-2 was as effective in the hamster system as in the mouse system (Sobotková et al, 1996) . In other experiments we presented evidence that protection against tumour development could also be induced by the simultaneous or preceding inoculation of HPV16-transformed hamster cells expressing the herpes simplex virus thymidine-kinase gene if followed by treatment with ganciclovir (GCV) (Vonka et al, 1998 ). Finally, we were able to induce partial immunity against these cells by immunization with plasmids carrying the HPV16 E6/E7 genes or activated H-ras oncogene .
In an effort to develop a system free of the major disadvantages of Syrian hamsters, i.e. their 'semisyngeneity' and a lack of reliable reagents needed for analysis of the immune responses, we recently established several HPV16-transformed mouse C57BL/6 cell lines. A protocol similar to that employed in the Syrian hamster system was used. In the present report we describe some of the basic properties of the transformed mouse cells and present data from immunization/challenge experiments designed to induce protection against these cells.
MATERIAL AND METHODS

Animals and cells
C57BL/6 mice (H-2
b ) (Charles Rivers, Germany) were used in this study. Animals were maintained under standard conditions and UKCCCR guidelines for the care and treatment of animals in experimental neoplasia were observed. Secondary cell cultures were prepared from the kidneys of an adult animal and grown in Dulbecco's Modified Eagle's Medium (D-MEM) (Sevac, Prague) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U ml -1 penicillin and 100 µg ml -1 streptomycin. CaSki cells have been derived from HPV16-positive human cervical cancer (Baker et al, 1987) . HEF cells are spontaneously immortalized cells isolated from a hamster embryo fibroblast culture (Kutinová 1975) . TC-1 cells have been prepared by transformation of C57BL/6 primary mouse lung cells with HPV-16 E6/E7 oncogenes and activated H-ras (Lin et al, 1996) and were kindly provided by Dr TC Wu (Johns Hopkins University, Baltimore). All cell lines were grown in EPL medium (Sevac, Prague) (Kutinová and Vonka, 1978) .
Plasmids
Plasmids p16HHMo (Vousden et al, 1988), pEJ6.6 (Shih and Weinberg, 1982) and pAG60 (Colbere-Garapin et al, 1981) , carrying, respectively, the HPV16 E6/E7 oncogenes, the human Hras oncogene activated by G12V mutation, and the neomycin resistance gene, were kindly donated by Drs K Vousden (Ludwig Institute for Cancer Research, London), M Dürst, and F Rössl (both DKFZ, Heidelberg), respectively. We compared the sequences of human and mouse H-ras proteins and found no mismatch. Therefore, the G12V mutation represents the only difference between the normal mouse H-ras protein and the human H-ras oncoprotein expressed from pEJ6.6.
Plasmids to be used in immunization experiments (see below) were propagated in Escherichia coli, XL1-blue strain, in Terrific Broth Medium with 100 µg ml -1 of ampicillin added. Plasmid DNA was extracted by alkaline lysis followed by CsCl gradient centrifugation. Purified DNA was dissolved in phosphate-buffered saline (PBS) and stored at -20˚C.
Cell transformation
Plasmids pEJ6.6 and p16HHMo were cotransfected, along with pAG60, into secondary mouse kidney cells. In the transfection, the lipofection reagent DOTAP (Boehringer, Mannheim) was used, following the manufacturer's instructions. Lines of transformed cells were established as described previously .
Analysis of nucleic acids
DNA was extracted from cell lines by the sodium dodecyl sulphate (SDS)-proteinase K-phenol-chloroform method (Blin and Stafford, 1976) . Total RNA was isolated using the RNA Blue Reagent (Top-Bio, Prague) (Chomczynski, 1993) . Southern blot hybridization and the reverse transcriptase-polymerase chain reaction (RT-PCR) were performed as described previously .
Immunoblotting
Material for the detection of the H-ras oncoprotein was prepared by lysis of cells with RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5). Secondary mouse kidney cells (MKC) were used as a negative control. Cell monolayers in 150 cm 2 bottles were washed with PBS and placed on ice. One millilitre of RIPA buffer precooled at +4˚C was added per bottle and the cells were incubated on ice for 30 min with occasional rocking. Lysed cells were collected by scraping and the cell debris in the lysis buffer was transferred into an Eppendorf tube and spun at 10 000 g for 10 min at +4˚C. Samples were further analysed by 10% SDS-PAGE. The proteins separated were electroblotted onto a nitrocellulose membrane and incubated, in PBS, with anti-pan-ras
Val-12 mouse antibody (Calbiochem, La Jolla, CA) diluted in 10% non-fat milk for 2 hours at room temperature or overnight at +4˚C. The blots were then washed 5 × 5 min with PBS/0.1% Tween, secondary peroxidase-labelled anti-mouse antibody was added, and the mixture was kept for 1 hour at room temperature. The blots were washed 8 × 5 min with PBS/0.1% Tween and specific antigens were detected using the ECL Plus system (Amersham, Little Chalfont, England).
Flow cytometry
Cells were harvested with trypsin and washed twice with PBS. 
Immunocytochemistry
MK16/1/IIIABC and TC-1 cells grown on plastic dishes were washed with PBS and fixed in a cold mixture of methanol and acetone (1:1 by volume) for 10 min. Cytokeratins were detected by standard immunostaining with antikeratin monoclonal antibodies C-11 (binds keratins 4, 5, 6, 10, 13 and 18) and C-22 (recognizes keratins 5 and 8) Bartkova et al, 1991) . Antibody DC-10 (Lauerova et al, 1988) , which reacts with human keratin 18 only, was used as a negative control. Peroxidase-or FITC-conjugated rabbit antisera against mouse immunoglobulins (DAKO, Glostrup, Denmark), diluted 1:50 and 1:20, respectively, were used as secondary antibodies. Where the peroxidase conjugate was employed, positive cells were stained with DAB (Sigma) and nuclei were counterstained with haematoxylin.
Tumour induction and growth
Cells were harvested with trypsin, washed three times with PBS and injected s.c. (0.2 ml) in the back of C57BL/6 mice. Tumour development was regularly monitored. In a DNA immunization experiment (see below), survival of tumour-bearing mice was recorded.
Student's t-test was used for statistical analysis. 
Tumour metastases
Mice were inoculated with 10 5 , 10 6 or 10 7 MK16/1/IIIABC cells. When their tumours reached approximately 1.5 cm in diameter, the mice were humanely killed and autopsied. Their lymph nodes, lungs, liver, heart and brain were examined histologically for the presence of spontaneous metastases. The organs were fixed in 10% neutral buffered formalin and embedded in paraffin. Sections were stained with haematoxylin and eosin.
Immunization with irradiated cells
Male mice, 6-8 weeks old, were immunized with two doses of irradiated (200 Gy) MK16/1/IIIABC cells: 10 6 cells were injected on day 0 and 10 7 cells on day 34. 20 days later, groups of 5 animals were challenged s.c. with 10 5 or 5×10 5 MK16/1/IIIABC cells, injected at a body site different from that used in immunization. Nonimmunized mice served as controls.
DNA immunization
Male mice, 6-8 weeks old, received three 100 µg i.m. doses of plasmid DNA in 50 µl PBS at 3-week intervals. Plasmid pBR322 served as a negative control. 10 days after the third immunization dose, groups of 8-9 animals were challenged s.c. in the back with 10 4 MK16/1/IIIABC cells.
Chemicals
Cyclophosphamide (Orion Corporation Farmos, Turku, Finland) was used for treating some of the mice (300 mg kg -1 body weight) prior to their inoculation with MK16/1 or MK16/1/IA cells.
RESULTS
Establishment of oncogenic mouse cell lines
Secondary kidney cells derived from C57BL/6 mice were contransfected with the following mixture of plasmids: p16HHMo, carrying the HPV16 oncogenes E6 and E7; pEJ6.6, carrying the activated human H-ras oncogene, and pAG60, carrying the neomycin resistance gene. Following selection with the neomycin analogue G418 (200 µg ml -1 ), a cell line designated MK16/1 was established. These cells (3.3 × 10 6 ) were inoculated s.c. into 3-week-old mice. Tumours developed in all 5 animals treated 1 day before inoculation with cyclophosphamide, but not in any of 8 cyclophosphamide-untreated mice. Several cell lines were derived from the tumours and one of them, MK16/1/IA, was inoculated (2 × 10 6 cells) into 3-4-month-old mice treated or untreated with cyclophosphamide. In this case, tumours developed not only in the treated animals but also in 2 of 3 untreated mice. From one of these, an MK16/1/IIAB cell line was isolated. These cells were again injected into untreated mice and several cell lines were derived from different tumours. For subsequent experiments the most oncogenic cell line, MK16/1/IIIABC, was selected. In different experiments 1 TID 50 dose ranged from 10 3.5 to 10 4.5 , depending on the age and sex of animals. The results of a representative experiment are shown in Figure 1 .
The tumours induced derived from low-differentiated epitheloid cells ( Figure 2A ). As angiogenesis in the tumours was low, large necroses were recorded in their centres (not shown). Despite infrequent invasive growth and the relatively rarely observed angioinvasivity of the MK16/1/IIIABC tumours (not shown), metastases were found in draining lymphatic nodes (11-25%) and in the lungs (75-80%) ( Figure 2B 
Nucleic-acid analysis of transformed cells
From the cell lines MK16/1, MK16/1/IA, MK16/1/IIAB and MK16/1/IIIABC, DNA and RNA were isolated. Southern blot hybridization of the DNAs, digested with the BamHI restriction enzyme, was performed using a 32 P-labelled probe specific for the HPV16 E6 gene ( Figure 3A) . Several bands were detected, with the band pattern being the same for all samples. This indicated stable integration of the viral DNA and a clonal origin of the cell lines.
Reverse-transcriptase PCR was used to examine unspliced and spliced forms of the E6/E7 transcripts ( Figure 3B ). Both unspliced E6 (PCR product, 420 bp) and spliced E6*I (238 bp) and E6*II (121 bp) forms were detected in all cell lines, with the unspliced E6 and spliced E6*I predominating. No marked differences among the different MK16/1 lines were observed.
Detection of activated H-ras by immunoblotting
Expression of the mutated H-ras oncoprotein in MK16/1/IIIABC cells was tested by immunoblotting ( Figure 3C ). Antibody specific for this protein detected one protein band corresponding in size (21 kDa) to the ras product. In secondary mouse kidney cells used as a negative control, only nonmutated H-ras protein was demonstrated with anti-pan-ras monoclonal antibody (Calbiochem) (data not shown).
Immunocytochemical detection of cytokeratins
To confirm the epithelial origin of MK16/1/IIIABC cells, expression of cytokeratins was tested. Simultaneously, TC-1 cells (Lin Complementary DNA prepared from total RNA was amplified with HPV16 E6/E7-specific primers. The products were analysed on 3% agarose gel. Three forms of transcript were detected: E6 (420 bp), E6*1 (238 bp), and E6*II (121 bp). The smallest product, E6*II, was demonstrated in all samples but is poorly visible on the picture. (C) Detection of activated H-ras by immunoblotting. Whole-cell lysates were boiled in electrophoresis sample buffer, separated by 10% SDS-PAGE and transferred onto a nitrocellulose membrane. Activated H-ras was detected with mouse monoclonal anti-pan-ras antibody. Secondary MKC were used as a negative control confirmed the above findings, i.e. there was strong fluorescence of keratin filaments with the C-11 (Figure 4 ) and C-22 (not shown) antibodies, while the DC-10 monoclonal antibody was completely negative. TC-1 cells exhibited only a diffuse background peroxidase staining with C-22 antibody but no filamentous network was seen; the C-11 and DC-10 antibodies gave negative staining.
Immunofluorescence examination of TC-1 cells gave negative reactions with all of the antibodies tested.
Testing for MHC class I and class II by flow cytometry
MHC class I and class II expression on MK16/1/IIIABC cells was examined by flow cytometry. As positive controls, secondary MKC and splenocytes were used, respectively. For comparison, TC-1 cells that had been reported to express MHC class I but not class II molecules were also stained. While secondary MKC and TC-1 cells were shown to contain MHC class I molecules, no MHC class I expression was detected on MK16/1/IIIABC cells ( Figure 5 ). Both TC-1 and MK16/1/IIIABC cells were MHC class II negative ( Figure 5 ).
Induction of antitumour immunity by immunization with irradiated cells
Lethally irradiated MK16/1/IIIABC cells were administered as described in Materials and Methods to induce protection against Figure 6A ), but the difference was not significant in comparison with control mice.
DNA immunization against tumours
Plasmids p16HHMo and pEJ6.6, used for malignant transformation of mouse kidney cells, were each tested as a prophylactic DNA vaccine. The immunization effect in mice challenged with 10 4 MK16/1/IIIABC cells was weak. Tumours formed in all animals, but some inhibition of tumour growth was recorded in the immunized mice and both plasmids prolonged their survival as compared with control, nonimmunized or pBR322-treated animals ( Figure 6B ). This difference was statistically significant (P < 0.03).
DISCUSSION
An oncogenic cell line, MK16/1/IIIABC, was obtained by transformation of secondary mouse kidney cells with the HPV16 E6/E7 and the mutated human H-ras oncogenes. The expression of activated H-ras in the cells was demonstrated by immunoblotting. Because of lack of reliable reagents, the E6 and E7 proteins were not detected. However, we assume they were also produced, because we showed the presence of unspliced and two spliced mRNAs that serve as transcripts for expression of both the E6 and E7 proteins. Moreover, it is reasonable to assume that without E6/E7 production oncogenic transformation of secondary mouse kidney cells would not have been achieved.
At present, TC-1 cells are increasingly utilized for the testing of anti-HPV therapeutic vaccines. Our MK16/1/IIIABC cells were obtained by transformation with the same oncogenes as TC-1 cells had been. Both cell lines originated from C57BL/6 mice; still, there are considerable differences between them. MK16/1/IIIABC were derived from secondary kidney cells, they have epitheloid morphology and strongly express a variety of cytokeratins, while TC-1 cells have been obtained from a lung cell culture, show fibroblastoid morphology and do not express any of the keratins tested in the present series of experiments. Furthermore, MK16/1/IIIABC cells are MHC class I-negative, while TC-1 cells are MHC class I-positive. Finally, subcutaneous tumours induced by MK16/1/IIIABC cells exhibited a strong metastatic potential (spontaneous lung metastases were observed in about 75% of tumour-bearing animals), while spontaneous metastases are extremely rare in animals with tumours formed after inoculation with TC-1 cells. Because of the latter two characteristics, MK16/1/IIIABC cells may serve as a highly suitable model for studying immune reactions against HPV16-associated human tumours. It should be remembered that in about 70% of CC the production of MHC class I molecules is downregulated and these patients have a worse prognosis (Connor et al, 1993; Keating et al, 1995) . It has also been reported that MHC class I expression in metastases is lower than in primary tumours (Cromme et al, 1994) .
We had previously shown in a hamster model that protection against tumour cells expressing HPV16 E6/E7 and activated H-ras oncoproteins could be induced by vaccination with plasmid DNA carrying either the E6/E7 (p16HHMo) or activated H-ras (pEJ6.6) oncogenes . Such immunization reduced tumour incidence from the 40-50% seen in the control group inoculated with pBR322 to about 10-20%. In the present model we attempted to immunize mice with the same plasmids following the same immunization scheme. However, the resulting protection was rather weak. We only recorded differences in tumour size, time of the appearance of tumours and length of survival of the animals, but not in the frequency of tumours formed. This might have been due to the properties of the challenging cells (no MHC class I and class II molecules, a low level of expression of E6/E7 and/or H-ras genes) and/or a low capability of C57BL/6 mice to mount an immune response against these oncoproteins under the experimental conditions used. However, other factors might also have been involved.
As MK16/1/IIIABC cells are both MHC class I and class II negative, cytotoxic CD 4+ and CD 8+ T cells could not be responsible for the protection against the MK16/1/IIIABC challenge. However, it has been suggested that CD4 + T helper cells play the central role in the immune response against tumour cells (Hung et al, 1998; Mumberg et al, 1999) . This response was mediated by activated macrophages and eosinophils (Hung et al, 1998) or by indirect effects of IFN-γ (Mumberg et al, 1999) . We suppose that similar mechanisms might also be induced in our tumour system.
To summarize, we isolated a line of oncogenic, HPV16-transformed epitheloid mouse cells, free of MHC class I molecules, which metastasize spontaneously. In the present study we only managed to induce weak protection against these cells, whether by immunization with DNA coding for E6/E7 or H-ras oncoproteins, or by vaccination with irradiated homologous cells. Therefore, we are presently trying to apply approaches that might enhance immunity against tumour cells without MHC class I expression. These experiments have already been started and some results have been reported (Bubeník et al, 1999) .
